JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Amicus Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

8.68 2.48

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.66

Max

8.73

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.7M

-24M

Verkäufe

29M

155M

Gewinnspanne

-15.787

Angestellte

499

EBITDA

-1M

-5.8M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+82.93% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

461M

2.3B

Vorheriger Eröffnungskurs

6.2

Vorheriger Schlusskurs

8.68

Nachrichtenstimmung

By Acuity

35%

65%

101 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Amicus Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Okt. 2025, 18:41 UTC

Ergebnisse

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24. Okt. 2025, 18:31 UTC

Ergebnisse

Correction to Procter & Gamble to Focus on Innovation

24. Okt. 2025, 16:25 UTC

Wichtige Markttreiber

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24. Okt. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Okt. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24. Okt. 2025, 21:07 UTC

Ergebnisse

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24. Okt. 2025, 20:58 UTC

Ergebnisse

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24. Okt. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Okt. 2025, 20:40 UTC

Ergebnisse

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24. Okt. 2025, 20:24 UTC

Ergebnisse

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. Okt. 2025, 20:23 UTC

Ergebnisse

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. Okt. 2025, 20:13 UTC

Ergebnisse

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24. Okt. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24. Okt. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24. Okt. 2025, 19:33 UTC

Ergebnisse

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24. Okt. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24. Okt. 2025, 18:52 UTC

Ergebnisse

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. Okt. 2025, 18:41 UTC

Ergebnisse

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. Okt. 2025, 18:03 UTC

Ergebnisse

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24. Okt. 2025, 18:02 UTC

Ergebnisse

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24. Okt. 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24. Okt. 2025, 16:57 UTC

Ergebnisse

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24. Okt. 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24. Okt. 2025, 16:44 UTC

Market Talk
Ergebnisse

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24. Okt. 2025, 16:39 UTC

Market Talk
Ergebnisse

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24. Okt. 2025, 16:33 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 16:23 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Okt. 2025, 16:07 UTC

Ergebnisse

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer-Vergleich

Kursveränderung

Amicus Therapeutics Inc Prognose

Kursziel

By TipRanks

82.93% Vorteil

12-Monats-Prognose

Durchschnitt 15.86 USD  82.93%

Hoch 20 USD

Tief 12 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amicus Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

7

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

5.925 / 7.38Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

101 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
help-icon Live chat